Literature DB >> 18663360

hPMC2 is required for recruiting an ERbeta coactivator complex to mediate transcriptional upregulation of NQO1 and protection against oxidative DNA damage by tamoxifen.

S P Sripathy1, L J Chaplin, N W Gaikwad, E G Rogan, M M Montano.   

Abstract

In the presence of ERbeta, trans-hydroxytamoxifen (TOT) protects cells against 17beta-estradiol (E(2))-induced oxidative DNA damage (ODD) and this correlates with increased expression of the antioxidative enzyme quinone reductase (QR). Here, we investigate the molecular mechanism responsible for ERbeta-mediated protection against ODD. We observe constitutive interaction between ERbeta and the novel protein hPMC2. Using a combination of breast epithelial cell lines that are either positive or negative for ERalpha, we demonstrate TOT-dependent recruitment of both ERbeta and hPMC2 to the EpRE (electrophile response element)-regulated antioxidative enzyme QR. We further demonstrate TOT-dependent corecruitment of the coactivators Nrf2, PARP-1 (poly (ADP-ribose) polymerase 1) and topoisomerase IIbeta, both in the presence and absence of ERalpha. However, absence of either ERbeta or hPMC2 results in nonrecruitment of PARP-1 and topoisomerase IIbeta, loss of antioxidative enzyme induction and attenuated protection against ODD by TOT even in the presence of Nrf2 and ERalpha. These findings indicate minor role for Nrf2 and ERalpha in TOT-dependent antioxidative gene regulation. However, downregulation of PARP-1 attenuates TOT-dependent antioxidative gene induction. We conclude that ERbeta and hPMC2 are required for TOT-dependent recruitment of coactivators such as PARP-1 to the EpRE resulting in the induction of antioxidative enzymes and subsequent protection against ODD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18663360      PMCID: PMC4094353          DOI: 10.1038/onc.2008.235

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice.

Authors:  M Ramos-Gomez; M K Kwak; P M Dolan; K Itoh; M Yamamoto; P Talalay; T W Kensler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  A system for stable expression of short interfering RNAs in mammalian cells.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Science       Date:  2002-03-21       Impact factor: 47.728

Review 3.  Glutathione-S-transferase family of enzymes.

Authors:  R C Strange; M A Spiteri; S Ramachandran; A A Fryer
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

4.  Molecular determinants for the tissue specificity of SERMs.

Authors:  Yongfeng Shang; Myles Brown
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

5.  Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta.

Authors:  E J Routledge; R White; M G Parker; J P Sumpter
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

6.  Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands.

Authors:  C W Wong; B Komm; B J Cheskis
Journal:  Biochemistry       Date:  2001-06-12       Impact factor: 3.162

Review 7.  Is estradiol a genotoxic mutagenic carcinogen?

Authors:  J G Liehr
Journal:  Endocr Rev       Date:  2000-02       Impact factor: 19.871

8.  Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.

Authors:  Nicole R Bianco; George Perry; Mark A Smith; Dennis J Templeton; Monica M Montano
Journal:  Mol Endocrinol       Date:  2003-04-24

9.  Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo.

Authors:  Kai-Ming Li; Rosa Todorovic; Prabu Devanesan; Sheila Higginbotham; Harald Köfeler; Ragulan Ramanathan; Michael L Gross; Eleanor G Rogan; Ercole L Cavalieri
Journal:  Carcinogenesis       Date:  2003-10-24       Impact factor: 4.944

10.  Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.

Authors:  Lori C Sakoda; Christie R Blackston; Kan Xue; Jennifer A Doherty; Roberta M Ray; Ming Gang Lin; Helge Stalsberg; Dao Li Gao; Ziding Feng; David B Thomas; Chu Chen
Journal:  Breast Cancer Res Treat       Date:  2007-07-12       Impact factor: 4.872

View more
  11 in total

1.  The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

Authors:  Marian Y Williams-Brown; Sana M Salih; Xia Xu; Timothy D Veenstra; Muhammad Saeed; Shaleen K Theiler; Concepcion R Diaz-Arrastia; Salama A Salama
Journal:  J Steroid Biochem Mol Biol       Date:  2011-05-10       Impact factor: 4.292

2.  Downregulation of hPMC2 imparts chemotherapeutic sensitivity to alkylating agents in breast cancer cells.

Authors:  Nirmala Krishnamurthy; Lili Liu; Xiahui Xiong; Junran Zhang; Monica M Montano
Journal:  Cancer Biol Ther       Date:  2015-04-07       Impact factor: 4.742

3.  Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer.

Authors:  Yuan Yao; Angela M H Brodie; Nancy E Davidson; Thomas W Kensler; Qun Zhou
Journal:  Breast Cancer Res Treat       Date:  2010-07-10       Impact factor: 4.872

Review 4.  Minireview: Estrogen receptor-beta: mechanistic insights from recent studies.

Authors:  Bonnie J Deroo; Adrian V Buensuceso
Journal:  Mol Endocrinol       Date:  2010-04-02

5.  Quinone Methide Bioactivation Pathway: Contribution to Toxicity and/or Cytoprotection?

Authors:  Judy L Bolton
Journal:  Curr Org Chem       Date:  2014-01-01       Impact factor: 2.180

6.  Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites.

Authors:  Margarita M Ivanova; Kristen H Luken; Amber S Zimmer; Felicia L Lenzo; Ryan J Smith; Maia W Arteel; Tara J Kollenberg; Kathleen A Mattingly; Carolyn M Klinge
Journal:  FASEB J       Date:  2011-01-13       Impact factor: 5.191

7.  Induction of quinone reductase by tamoxifen or DPN protects against mammary tumorigenesis.

Authors:  Nirmala Krishnamurthy; Yanduan Hu; Sandra Siedlak; Yong Qiu Doughman; Michiko Watanabe; Monica M Montano
Journal:  FASEB J       Date:  2012-06-14       Impact factor: 5.191

8.  Aberrant Keap1 methylation in breast cancer and association with clinicopathological features.

Authors:  Raffaela Barbano; Lucia Anna Muscarella; Barbara Pasculli; Vanna Maria Valori; Andrea Fontana; Michelina Coco; Annamaria la Torre; Teresa Balsamo; Maria Luana Poeta; Giovanni Francesco Marangi; Evaristo Maiello; Marina Castelvetere; Fabio Pellegrini; Roberto Murgo; Vito Michele Fazio; Paola Parrella
Journal:  Epigenetics       Date:  2012-12-18       Impact factor: 4.528

Review 9.  Transcriptional roles of PARP1 in cancer.

Authors:  Matthew J Schiewer; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2014-06-10       Impact factor: 5.852

10.  Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita.

Authors:  Michelle L Kerns; Jill M C Hakim; Abigail Zieman; Rosemary G Lu; Pierre A Coulombe
Journal:  J Invest Dermatol       Date:  2017-12-24       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.